Document:

EX-10.11

 Exhibit 10.11 

ACRIVON THERAPEUTICS, INC. 

NON-EMPLOYEE DIRECTOR COMPENSATION
POLICY 
 Each member of the Board of Directors (the “Board”) of Acrivon Therapeutics, Inc. (the
“Company”) who is a non-employee director of the Company (each, a “Non-Employee Director”) will receive the compensation
described in this Non-Employee Director Compensation Policy (this “Director Compensation Policy”) for his or her Board service upon and following the effective date of the
execution of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock (such stock, the “Common Stock” and such date, the “IPO
Date”), subject to the terms and conditions set forth herein. 
 This Director Compensation Policy may be amended or modified,
or any provision of it waived, at any time in the sole discretion of the Board. Any Non-Employee Director may decline all or any portion of his or her cash or equity compensation in any period in such Non-Employee Director’s sole discretion prior to the date cash may be paid or equity awards are to be granted, as the case may be. 

Annual Cash Compensation 
 The annual cash
compensation amounts set forth below will be payable in equal quarterly installments in arrears on or promptly following the end of each fiscal quarter in which the service occurred, prorated for any partial months of service. All annual cash fees
are vested upon payment. 
 Commencing on the IPO Date, each Non-Employee Director will be eligible
to receive the following annual cash retainers for service on the Board (as applicable): 
  

	1.	 Annual Board Service Retainer: 

	 	(a)	 All Eligible Directors: $40,000 

	 	(b)	 Lead Independent Director: $20,000 (in addition to the regular Annual Board Service Retainer)

  

	2.	 Annual Committee Chair Service Retainer: 

	 	(a)	 Chair of the Audit Committee: $15,000 

	 	(b)	 Chair of the Compensation Committee: $15,000 

	 	(c)	 Chair of the Nominating and Corporate Governance Committee: $10,000 

 

	3.	 Annual Committee Member Service Retainer (not applicable to Committee Chairs): 

	 	(a)	 Member of the Audit Committee: $7,500 

	 	(b)	 Member of the Compensation Committee: $7,500 

	 	(c)	 Member of the Nominating and Corporate Governance Committee: $5,000 

Expenses 
 The Company will reimburse each
Non-Employee Director for any ordinary and reasonable out-of-pocket expenses actually incurred by such director in connection
with in-person attendance at and participation in Board and committee meetings; provided, that such director timely submits to the Company appropriate documentation substantiating such expenses in accordance
with the Company’s travel and expense policy as in effect from time to time. 

 Equity Compensation 

Commencing on the IPO Date, each eligible Non-Employee Director will be eligible to receive the equity
compensation set forth below. Equity awards will be granted under the Company’s 2022 Equity Incentive Plan, as the same may be amended from time to time, or any successor plan thereto (the “Plan”). All stock options
granted under this policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying Common Stock on the date of grant, and a term of ten years from the date
of grant (subject to earlier termination in connection with a termination of service as provided in the Plan). 

1.    Initial Option Grant. On appointment to the Board, and without any further action of the Board, at the close
of business on the date of such appointment (or, if such date is not a market trading day, the first market trading day thereafter), each individual who becomes a Non-Employee Director after the IPO Date will
automatically be granted a stock option having an aggregate grant date fair value of $315,000 (the “Initial Option Grant”); provided, however, that the number of shares underlying each Initial Option Grant shall not
exceed 32,500 shares, subject to any adjustments as necessary to implement any Capitalization Adjustments (as defined in the Plan) that occur after the IPO Date. The number of shares subject to each Initial Option Grant shall be determined as set
forth under Section 4 below. The shares subject to each Initial Option Grant will vest in substantially equal monthly installments over a three-year period such that the option is fully vested on the third anniversary of the date of grant,
subject to the Non-Employee Director’s Continuous Service (as defined in the Plan) through each applicable vesting date. 

2.    Annual Option Grant. Without any further action of the Board, at the close of business on the date of each
annual meeting of the Company’s stockholders following the IPO Date (each, an “Annual Meeting”), commencing on the date of the 2024 Annual Meeting, each person who is then a
Non-Employee Director will automatically be granted a stock option having an aggregate grant date fair value of $210,000 (the “Annual Option Grant”); provided, however, that the
number of shares underlying each Annual Option Grant shall not exceed 20,275 shares, subject to any adjustments as necessary to implement any Capitalization Adjustments that occur after the IPO Date. The number of shares subject to each Annual
Option Grant shall be determined as set forth under Section 4 below. The grant date fair value of the Annual Option Grant will be prorated for each individual who has been in service with the Company as a
Non-Employee Director for less than one year as of such Annual Meeting. The grant date fair value of such prorated Annual Option Grant shall be equal to $210,000 multiplied by a fraction, (i) in the case
of a grant made at the first Annual Meeting, the numerator of which is the number of days between commencement of service as a Non-Employee Director and the date of the Annual Meeting (provided, that for any Non-Employee Director who was a director of the Company at the IPO Date such number shall be 365), and the denominator of which is 365, or (ii) in the case of a grant made after the first Annual Meeting, the
numerator of which is the number of days between commencement of service as a Non-Employee Director and the date of such Annual Meeting, and the denominator of which is 365. Each Annual Option Grant will vest
on the earlier of the first anniversary of the date of grant or the date immediately preceding the date of the following Annual Meeting, subject to the Non-Employee Director’s Continuous Service through
each applicable vesting date. 
 3.    Change in Control. Notwithstanding anything herein to the contrary, for
each Non-Employee Director who remains in Continuous Service with the Company until immediately prior to the occurrence of a Change in Control (as defined in the Plan), each outstanding Initial Option Grant
and Annual Option Grant will become fully vested immediately prior to the occurrence of such Change in Control. 

4.    Determination of Number of Shares of Common Stock Subject to Grant. The number of shares of Common Stock
subject to any Initial Option Grant and Annual Option Grant made under this Director Compensation Policy will be determined using a Black-Scholes methodology as of the applicable grant date. 

 5.    Remaining Terms. The remaining terms and conditions of each
Initial Option Grant and Annual Option Grant, including transferability, will be as set forth in the Company’s Stock Option Grant Notice and Agreement pursuant to the Plan, in the form adopted from time to time by the Board or Compensation
Committee. 
 Non-Employee Director Compensation Limit 

Notwithstanding anything herein to the contrary, the cash compensation and equity compensation that each
Non-Employee Director is eligible to receive under this Director Compensation Policy shall be subject to the limits set forth in the Plan. 

* * * * *EX-10.1

  		 

  Exhibit 10.1

   

  CONSULTING AGREEMENT

  This Consulting Agreement (this “Agreement”) is made and entered into by and between Brandy Green (“CONSULTANT”) and Accuray Incorporated (“ACCURAY”), effective as of September 2, 2022 (“Effective Date”).  

  W I T N E S S E T H

  WHEREAS, CONSULTANT voluntarily resigned from CONSULTANT’s employment with ACCURAY effective September 1, 2022;

  WHEREAS, CONSULTANT has training, expertise and prior experience in acting as the VP, Controller and Interim Chief Financial Officer of ACCURAY; 

  WHEREAS, ACCURAY desires to retain CONSULTANT to provide the consulting services specified in this Agreement; and

  WHEREAS, CONSULTANT desires to provide consulting services for the benefit of ACCURAY and its related entities using CONSULTANT’s knowledge, skills, experience and abilities; 

  NOW THEREFORE, in consideration of the mutual promises contained herein, and other good and valuable consideration, the parties hereto agree as follows:

  ARTICLE I - SERVICES TO BE PROVIDED

  A.  Nature of Services.  CONSULTANT shall provide any reasonably requested transition services to ACCURAY, including without limitation assistance with any projects and initiatives in which CONSULTANT was involved during CONSULTANT’s tenure as an employee of ACCURAY, global tax consulting, assistance with ACCURAY’s FY22 Proxy Statement, and assistance familiarizing any successor of CONSULTANT to the controller role (collectively, “Services”), with a maximum of 40 hours of Services each month during the Term (as defined below) of this Agreement.  

  B.  Right of Control.  CONSULTANT shall have exclusive control over the means, manner, methods and processes by which the Services are performed.

  C.  Exclusive Services.  In order to ensure that CONSULTANT is available to provide, and to devote CONSULTANT’S undivided attention and effort in providing, the Services as required by ACCURAY, and to insure compliance with the obligations in Article IV of this Agreement, CONSULTANT agrees that CONSULTANT will not accept any employment or engage in any other consulting, business and/or commercial activities with the following entities: Varian Medical Systems, Elekta AB, Siemens AG, Brainlab AG, RaySearch Laboratories, ViewRay Inc., Zap Surgical Systems, Inc., RefleXion Medical, Inc., Best Medical, Rotary 

  	1

  

  						 

   

  Systems, or any of their respective affiliates (the “Prohibited Entities”) without the approval of ACCURAY’s Chief Executive Officer.  In addition, in the event CONSULTANT intends to provide services related in any way to radiation oncology, including radiosurgery or radiation therapy, during the Term of this Agreement to any entity other than a Prohibited Entity, CONSULTANT shall notify ACCURAY’s Chief Executive Officer to get approval, which approval shall not be unreasonably withheld.

  ARTICLE II - COMPENSATION FOR SERVICES

  A.  Consulting Consideration.  As sole consideration for CONSULTANT’s performance of the Services, ACCURAY shall provide CONSULTANT with:

  (1)continued vesting of CONSULTANT’S outstanding ACCURAY equity awards as detailed in subsection B below; and

  (2)payment of the bonus CONSULTANT would have received under ACCURAY’s Company Bonus Plan for fiscal 2022, taking into account the approved 80% bonus pool funding level, as if CONSULTANT had remained employed by ACCURAY through the date that would have otherwise been required to earn the bonus, which amount will be paid at the same time as bonuses are paid under the Company Bonus Plan to the U.S. employees of ACCURAY (the “Bonus Payment Date”); provided, however, that CONSULTANT will not be eligible to receive such bonus if this Agreement is terminated by ACCURAY for Cause (as defined below) or if this Agreement is terminated for convenience by CONSULTANT, in each case prior to the Bonus Payment Date.

  B.  Equity. No additional equity will be granted under this Agreement, however, any currently outstanding equity awards granted by ACCURAY to CONSULTANT shall continue to vest in accordance with the terms thereof until the expiration or earlier termination of the Term.  

  C.  No Reimbursement of Expenses. ACCURAY will not reimburse CONSULTANT for any out-of-pocket expenses.

  D.  Tax Obligations.  CONSULTANT understands and agrees that all compensation to which CONSULTANT is entitled under the Agreement shall be reported on an IRS Form 1099, and that CONSULTANT is solely responsible for all income and/or other tax obligations, if any, including but not limited to all reporting and payment obligations, if any, which may arise as a consequence of any payment under this Agreement.

  E.  No Benefits.  CONSULTANT understands and agrees that since CONSULTANT is no longer an employee of ACCURAY, CONSULTANT shall not, except as expressly set forth in Section B of Article II above, be entitled to participate in ACCURAY employee benefits plans or receive any benefits provided to employees of ACCURAY, including, but not limited to participation in retirement savings or benefit plans, bonus plans and/or stock option plans beyond CONSULTANT’s participation during CONSULTANT’s employment by ACCURAY; holidays off with pay; vacation time off with pay; paid leaves of absence of any kind; and insurance coverage of any kind, specifically including, but not limited to, medical and dental insurance, workers’ compensation insurance and state disability insurance, but excluding any 

  2		

  

  						 

   

  insurance coverage CONSULTANT may be entitled to that extend, pursuant to its terms, through the last day of the month in which CONSULTANT ceased to be an employee of ACCURAY, which insurance coverage will terminate as of the last day of such month.

  ARTICLE III - TERM AND TERMINATION

  A.  Term of Agreement.  This Agreement shall continue in full force and effect from the Effective Date through December 31, 2022 unless earlier terminated pursuant to subsection B or C below (the “Term”).  

  B.  Termination for Convenience.  CONSULTANT may terminate this Agreement for convenience upon thirty (30) days prior written notice to ACCURAY.

  C.  Termination For Cause.  ACCURAY may terminate this Agreement for Cause at any time without any prior notice, except to the extent provided in the last sentence of this subsection.  As used herein, “Cause” shall mean any of the following conduct: (i) CONSULTANT’s revocation of the Separation Agreement and General Release signed by CONSULTANT of even date herewith; (ii) CONSULTANT’s material breach of this Agreement or any confidentiality or invention assignment agreement between CONSULTANT and ACCURAY, or of an ACCURAY policy or of a law, rule or regulation applicable to ACCURAY or its operations; (iii) CONSULTANT’s neglect of duties, or failure or refusal to perform the material duties under this Agreement, or failure to follow the reasonable and lawful instructions of ACCURAY; (iv) any dishonesty, self-dealing, fraud, misconduct, disparagement of ACCURAY or ACCURAY employees, or other similar conduct by CONSULTANT that ACCURAY reasonably determines has caused, is causing or reasonably is likely to cause harm to ACCURAY; or (v) CONSULTANT’s conviction of or plea of guilty or nolo contendere to any crime (other than a traffic offense that is not punishable by a sentence of incarceration). Termination pursuant to clause (iii) in the preceding sentence shall be deemed to be for Cause only if such failure continues after CONSULTANT has been given written notice thereof and fifteen (15) business days thereafter in which to present CONSULTANT’s position to ACCURAY or to cure the same, unless ACCURAY reasonably determines that the reason(s) for termination are not capable of being cured. 

  ARTICLE IV -- PROPRIETARY RIGHTS

  A.  No Impediments to Providing Consulting Services.  CONSULTANT represents that CONSULTANT is not party to any agreement with any individual or business entity, including any relating to protection of alleged trade secrets or confidential business information that would prevent CONSULTANT from providing the Services or that would be violated by the providing of the Services.

  B.  Confidential and Proprietary Information.  CONSULTANT acknowledges that the post-employment terms of the ACCURAY Employee Invention Assignment and Confidentiality Agreement and any offer letter between ACCURAY and CONSULTANT that existed before this Agreement and any release agreement that may be entered into between ACCURAY and CONSULTANT, remain in full force and effect, specifically including the prohibitions against using or disclosing any of ACCURAY’s trade secrets or proprietary and/or 

  3		

  

  						 

   

  confidential information learned while employed by ACCURAY.  CONSULTANT also acknowledges that during the Term, CONSULTANT will have access to and learn additional confidential information and/or trade secrets regarding the business of ACCURAY and its related entities, including, but not limited to, radiosurgery and radiation therapy devices, and various other business, financial, technical and employee information (collectively, “Confidential and Proprietary Information”).  

  C.  Restrictions on Use and Disclosure of Confidential and Proprietary Information.  In addition to the confidential information obligations that continue from the period of CONSULTANT’s employment with ACCURAY, CONSULTANT agrees to hold all Confidential and Proprietary Information in trust and in the strictest of confidence, and to protect the Confidential and Proprietary Information from disclosure, and to only use such Confidential and Proprietary Information as required to perform the Services hereunder.  CONSULTANT further agrees that CONSULTANT will not, directly or indirectly, use, publish, disseminate or otherwise disclose any Confidential and Proprietary Information to any third party without the prior written consent of ACCURAY, which may be withheld in its absolute discretion.  

  D.  Return of Property.  CONSULTANT agrees not to remove any property of ACCURAY or its related entities from their premises without express permission, and to return all such property, including computer data, written materials provided to or obtained during the term of this Agreement, customer and supplier address lists, and any other items of value at the time this Agreement is terminated.

  E.  Violations.  CONSULTANT agrees that ACCURAY and its related entities would be irreparably harmed by any actual or threatened violation of the promises in this Article IV, and therefore, that, in addition to other remedies, ACCURAY and its related entities will be entitled to an injunction prohibiting CONSULTANT from committing any such violations.

  ARTICLE V -- MISCELLANEOUS PROVISIONS

  A.  Independent Contractor Status.  CONSULTANT understands and agrees that CONSULTANT is an independent contractor and not an employee of ACCURAY and that CONSULTANT shall not become an employee of ACCURAY by virtue of the performance of the services called for under this Agreement.

  B.  No Office Space.  CONSULTANT understands and agrees that CONSULTANT will not be provided with a regular office at ACCURAY.  

  C.  Subconsultants and Other Contractors.  CONSULTANT is not authorized to engage the services of subconsultants, vendors or other contractors on behalf of ACCURAY or its related entities, unless CONSULTANT has obtained written authorization from ACCURAY to do so in advance.  To the extent such advance authorization has been obtained, ACCURAY will pay for the services provided by such subconsultants, vendors and/or other contractors. 

  D.  No Purchases.  CONSULTANT shall not purchase materials or supplies for the accounts of ACCURAY or its related entities, or otherwise hold CONSULTANT out as being authorized to make purchases for which ACCURAY or its related entities would be billed directly 

  4		

  

  						 

   

  by the seller of the materials or supplies, unless such purchase is authorized in writing by ACCURAY in advance.  

  E.  Compliance with Governmental Requirements.  CONSULTANT will maintain in force and/or secure all required licenses, permits, certificates and exemptions necessary for the performance of CONSULTANT’s services under this Agreement, and at all times shall comply with all applicable federal, state and local laws, regulations and orders.

  F.  Indemnification.  CONSULTANT shall indemnify and hold ACCURAY and its related entities, and the directors, officers, agents, representatives and employees of all such entities, harmless from and against any and all liabilities, losses, damages, costs, expenses, causes of action, claims, suits, legal proceedings and similar matters, including without limitation reasonable attorneys’ fees, resulting from or arising out of the failure of CONSULTANT or any of CONSULTANT’s employees to comply with and perform fully the obligations hereunder, or resulting from any act or omission on the part of CONSULTANT, provided however that the indemnification shall not apply to any good faith action on the part of the CONSULTANT that is within the scope of this Agreement.  If any cause of action, claim, suit or other legal proceeding is brought against CONSULTANT in connection with any services rendered under this Agreement, CONSULTANT shall promptly notify ACCURAY upon learning of any such proceeding.

  G.  Notices.  Any and all notices and other communications hereunder shall have been deemed to have been duly given when delivered personally or by e-mail during normal business hours, or 24 hours after being emailed outside of normal business hours or mailed, certified or registered mail, return receipt requested, postage prepaid, in the English language, to the addresses set forth below the signatures of the parties hereto or to such other address as either of the parties hereto may from time-to-time designate to the other party in writing.

  H.  Waiver.  No purported waiver by either party hereto of any provision of this Agreement or of any breach thereof shall be deemed a waiver of such provision or breach unless such waiver is in writing signed by the party making such waiver.  No such waiver shall be deemed to be a subsequent waiver of such provision or waiver of any subsequent breach of the same or any other provision hereof.

  I.  Severability.  The provisions of this Agreement are severable, and if any part of it is found to be unenforceable, the other paragraphs shall remain fully valid and enforceable.

  J.  Arbitration.  This Agreement shall in all respects be interpreted and governed by and under the laws of the State of California.  Any dispute between the parties hereto, including any dispute regarding any aspect of this Agreement or any act which allegedly has or would violate any provision of this Agreement or any law, will be resolved in accordance with the arbitration provisions set forth in CONSULTANT’s first fully-executed offer letter with ACCURAY for the VP, Controller position.  This section shall not restrict the right of ACCURAY to go to court seeking injunctive relief for a violation of Article IV of this Agreement, pending the outcome of an arbitration proceeding.  

  K.  Sole and Entire Agreement.  This Agreement sets forth the entire agreement between the parties hereto pertaining to the subject matter hereof, and fully supersedes any and all 

  5		

  

  						 

   

  prior agreements or understandings between the parties hereto, whether written or oral, pertaining to the subject matter hereof.  No change in, modification of, or addition, amendment or supplement to this Agreement shall be valid unless set forth in writing and signed and dated by each of the parties hereto subsequent to the execution of this Agreement.

  [REMAINDER OF PAGE INTENIONALLY LEFT BLANK]

   

   

   

  IN WITNESS WHEREOF, the parties have caused this Agreement to be executed as of the Effective Date set forth above.

  		
	 
/s/ Brandy Green
	ACCURAY INCORPORATED

	Brandy Green
	 

	 
	 

	Date:
	By:  /s/ Jesse Chew

	Address: 
Most recent on file with the Company
	Name: Jesse Chew	
Title:   General Counsel
Date:  
 
Address:  1310 Chesapeake Terrace
                 Sunnyvale, CA 94089

   

  6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]